Education
About Us
Working with TipRanks
Follow Us
Dermapharm Holding SE (DE:DMP)
XETRA:DMP
DMP Stock Chart & Stats
€37.30
€0.00(0.00%)
At close: 4:00 PM EST
€37.30
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€31.70 - €42.50
Previous CloseN/A
Volume747.00
Average Volume (3M)18.50K
Market Cap
€1.99B
Enterprise Value€0.00
Total Cash (Recent Filing)€146.58M
Total Debt (Recent Filing)€1.01B
Price to Earnings (P/E)17.2
Beta0.47
Next Earnings
Apr 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.43%
Share Statistics
EPS (TTM)0.76
Shares Outstanding53,840,000
10 Day Avg. Volume17,993
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.47
Price to Sales (P/S)1.77
P/FCF Ratio12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.00Price Target Upside-8.85% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsAdj. EBITDA improved to €88m, translating into a better margin of 29.8%, driven by both BP and OHP.
International ExpansionDermapharm's core business in Branded Pharma continues to grow at an org. mid- to high-single digit trajectory with some improvements to the already high margin profile as the company expands its internationalisation efforts across key therapeutic areas.
Sales StrategyManagement shifted its approach, focusing its sales force to engage with pharmacists in medical discussions about product efficacy and advantages.
Bears Say
Growth ChallengesGuidance was confirmed, implying a step-up in 4Q growth towards +10% on sales and +22% adj. EBITDA to meet consensus which looks rather challenging in light of current momentum and only -2% sales growth after 9M.
Sales PerformanceThere was still no meaningful turnaround in OHP with another decline in sales (-3% YoY) despite the seasonally stronger post-summer 3Q for Arkopharma.
Strategic RealignmentThe muted Arkopharma performance and the strategic realignment in Parallel Import feed the narrative of a rather transitionary FY25e with only stalling group sales growth.
Dermapharm Holding SE News
DMP FAQ
What was Dermapharm Holding SE’s price range in the past 12 months?
Dermapharm Holding SE lowest stock price was €31.70 and its highest was €42.50 in the past 12 months.
What is Dermapharm Holding SE’s market cap?
Dermapharm Holding SE’s market cap is €1.99B.
When is Dermapharm Holding SE’s upcoming earnings report date?
Dermapharm Holding SE’s upcoming earnings report date is Apr 15, 2026 which is in 115 days.
How were Dermapharm Holding SE’s earnings last quarter?
Dermapharm Holding SE released its earnings results on Nov 13, 2025. The company reported €0.76 earnings per share for the quarter, beating the consensus estimate of N/A by €0.76.
Is Dermapharm Holding SE overvalued?
According to Wall Street analysts Dermapharm Holding SE’s price is currently Overvalued.
Does Dermapharm Holding SE pay dividends?
Dermapharm Holding SE pays a Annually dividend of €0.9 which represents an annual dividend yield of 2.43%. See more information on Dermapharm Holding SE dividends here
What is Dermapharm Holding SE’s EPS estimate?
Dermapharm Holding SE’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dermapharm Holding SE have?
Dermapharm Holding SE has 53,840,000 shares outstanding.
What happened to Dermapharm Holding SE’s price movement after its last earnings report?
Dermapharm Holding SE reported an EPS of €0.76 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.029%.
Which hedge fund is a major shareholder of Dermapharm Holding SE?
Currently, no hedge funds are holding shares in DE:DMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dermapharm Holding SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€34.00 (-8.85% Downside)
€34.00 (-8.85% Downside)
Insider Transactions
Bought Shares
Worth €90.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.13%
12-Months-Change
Fundamentals
Return on Equity
18.82%
Trailing 12-Months
Asset Growth
-3.24%
Trailing 12-Months
Company Description
Dermapharm Holding SE
Dermapharm Holding SE (DMP) is a leading German pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality generic and specialty pharmaceuticals. The company operates primarily in the pharmaceutical sector, focusing on various therapeutic areas including dermatology, oncology, and neurology. Dermapharm offers a diverse portfolio of products, including prescription medications, over-the-counter drugs, and active pharmaceutical ingredients, leveraging its robust research and development capabilities to address unmet medical needs.
DMP Stock 12 Month Forecast
Average Price Target
€34.00
▼(-8.85% Downside)
Technical Analysis
Medios AG
―
PAUL HARTMANN AG
―
APONTIS PHARMA AG
―
PharmaSGP Holding SE
―
MPH Health Care AG
―
Options Prices
Currently, No data available
---